The 31 most recent market catalysts affecting $TEM, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 21, 2026
Corporate Catalyst
Bullish
Impact 65
Tempus AI Extends Recursion Data Deal Through 2029, Replacing Potential $84M Fees With $42M In Committed Payments, In Addition To Licensing Recursion’s RNA Foundation Model "TxFM" Under A Separate License Agreement
Tempus AI (TEM) and Recursion Pharmaceuticals (RXRX) have extended their data partnership through November 2029. This is significant because Tempus secures continued access to Recu…
Sep 21, 2026
Corporate Catalyst
Neutral
Impact 65
Goldman Sachs Initiates Coverage On Tempus AI with Neutral Rating, Announces Price Target of $75
Goldman Sachs, a prominent investment bank, has initiated coverage on Tempus AI (TEM) with a 'Neutral' rating and a $75 price target. This event is significant because it marks the…
Sep 18, 2026
Market Technicals
Bearish
Impact 55
Why Is Tempus AI Stock Falling Friday?
Tempus AI (TEM) stock experienced a decline on Friday, primarily due to a broader market weakening and profit-taking after a strong multi-day rally. The rally was driven by CEO Eri…
Sep 11, 2026
Corporate Catalyst
Bullish
Impact 55
HC Wainwright & Co. Maintains Buy on Tempus AI, Raises Price Target to $66
HC Wainwright & Co. analyst Yi Chen maintained a 'Buy' rating on Tempus AI (TEM) and raised the price target from $56 to $66. This analyst action signals continued confidence in th…
Sep 9, 2026
Corporate Catalyst
Bullish
Impact 75
Tempus AI Selected By Advanced Research Projects Agency For Health To Be Awarded $9.5M For First Autonomous Clinical AI Agent
Tempus AI (TEM) announced it has been selected by ARPA-H to receive up to $9.5 million to develop an autonomous clinical AI agent for heart failure. This is a significant positive …
Sep 9, 2026
Corporate Catalyst
Neutral
Impact 55
UBS Initiates Coverage On Tempus AI with Neutral Rating, Announces Price Target of $70
UBS analyst Doug Schenkel has initiated coverage on Tempus AI (TEM) with a Neutral rating and a $70 price target. This event is significant for Tempus AI as it marks the formal ent…
Sep 8, 2026
Corporate Catalyst
Neutral
Impact 55
Rothschild & Co Initiates Coverage On Tempus AI with Neutral Rating, Announces Price Target of $67
Rothschild & Co analyst Jamie Clark has initiated coverage on Tempus AI (TEM) with a 'Neutral' rating and a price target of $67. This event is significant for Tempus AI as it marks…
Sep 8, 2026
Corporate Catalyst
Neutral
Impact 55
Roth Capital Initiates Coverage On Tempus AI with Neutral Rating, Announces Price Target of $67
Roth Capital's initiation of coverage on Tempus AI (TEM) with a 'Neutral' rating and a $67 price target is a notable event for the company. For newly public companies, analyst cove…
Sep 2, 2026
Corporate Catalyst
Bullish
Impact 75
Tempus AI's Data Business Is Priced Like a Vendor, Not a Platform, Analyst Says
Cantor Fitzgerald initiated coverage on Tempus AI (TEM) with an 'Overweight' rating and an $80 price target, significantly above its current trading price. The core of the analyst'…
Sep 2, 2026
Corporate Catalyst
Bullish
Impact 75
TEM stock has given up its prior gain. Tempus AI shares were trading higher after Cantor Fitzgerald initiated coverage on the stock with an Overweight rating and announced an $80 price target.
The initiation of coverage by a reputable firm like Cantor Fitzgerald with an 'Overweight' rating and a substantial price target is typically a significant positive catalyst for a …
Sep 2, 2026
Corporate Catalyst
Bullish
Impact 75
Tempus AI shares are trading higher after Cantor Fitzgerald initiated coverage on the stock with an Overweight rating and announced an $80 price target.
This headline represents a significant corporate catalyst for Tempus AI. Analyst initiation with a positive rating ('Overweight') and a substantial price target ($80) often acts as…
Sep 2, 2026
Corporate Catalyst
Neutral
Impact 65
Cantor Fitzgerald Initiates Coverage On Tempus AI with Overweight Rating, Announces Price Target of $80
Cantor Fitzgerald's initiation of coverage on Tempus AI (TEM) with an 'Overweight' rating and an $80 price target is a significant event for the newly public company. This provides…
Sep 2, 2026
Corporate Catalyst
Neutral
Impact 65
Cathie Wood Sells $15.6 Million of Tempus AI Stock After Merck-Moderna Trial Win, Ark Keeps Selling AMD Shares
Cathie Wood's Ark Invest made notable portfolio adjustments. The sale of $15.6 million in Tempus AI (TEM) shares comes after a significant price surge, likely representing profit-t…
Sep 1, 2026
Corporate Catalyst
Bullish
Impact 65
Piper Sandler Upgrades Tempus AI to Overweight, Raises Price Target to $76
Piper Sandler analyst David Westenberg upgraded Tempus AI (TEM) from Neutral to Overweight and raised the price target from $56 to $76. This analyst action signals a more optimisti…
Aug 24, 2026
Corporate Catalyst
Bearish
Impact 65
What’s Going On With Tempus AI Stock on Monday?
Tempus AI's stock is experiencing a short-term pullback after a substantial 20% surge, which was primarily fueled by positive clinical trial results from Merck and Moderna for an a…
Aug 24, 2026
Corporate Catalyst
Bullish
Impact 65
Tempus AI Receives FDA Clearance For Tempus ECG-PH For Signs Associated With Pulmonary Hypertension
Tempus AI (TEM) has received FDA 510(k) clearance for its Tempus ECG-PH, an AI-powered device that analyzes standard ECGs for signs of pulmonary hypertension. This is a significant…
Aug 20, 2026
Corporate Catalyst
Bullish
Impact 75
Tempus AI shares are trading higher after BTIG maintained its Buy rating on the stock and raised its price target from $70 to $80.
This headline indicates a significant positive catalyst for Tempus AI (TEM). An analyst firm maintaining a 'Buy' rating and, more importantly, raising its price target, suggests a …
Aug 20, 2026
Corporate Catalyst
Bullish
Impact 85
Why Is Tempus AI Stock Gaining Thursday?
Tempus AI (TEM) stock is experiencing a significant uplift due to a combination of factors. BTIG maintained a Buy rating and raised its price target to $80, signaling strong analys…
Aug 20, 2026
Corporate Catalyst
Bullish
Impact 55
BTIG Maintains Buy on Tempus AI, Raises Price Target to $80
BTIG analyst Mark Massaro has maintained a 'Buy' rating on Tempus AI (TEM) and raised the price target from $70 to $80. This action signals increased confidence from the analyst in…
Aug 19, 2026
Corporate Catalyst
Bullish
Impact 95
Tempus AI Soars as Merck-Moderna Cancer Trial Validates Personalis Acquisition
Merck and Moderna announced successful Phase 3 trial results for their personalized mRNA cancer therapy, INTerpath-001, which significantly improved recurrence-free survival in mel…
Aug 7, 2026
Corporate Catalyst
Bullish
Impact 65
Why Is Tempus AI Stock Surging on Friday?
Tempus AI (TEM) is experiencing a significant stock surge, primarily driven by a positive sentiment shift across the AI-healthcare technology sector. This rally was ignited by Doxi…
Aug 4, 2026
Corporate Catalyst
Bullish
Impact 65
Tempus AI Announces Publication Of Study Results In 'Nature Medicine' That Demonstrate The PRISM2 Pathology Foundation Model's Ability To Perform Clinically Important Diagnostic Tasks
Tempus AI's announcement of the 'Nature Medicine' publication validates the efficacy and advanced capabilities of its PRISM2 AI model. This is significant because 'Nature Medicine'…
Jul 31, 2026
Corporate Catalyst
Bearish
Impact 85
Tempus AI Stock Slides Friday: What's Driving the Post-Earnings Reset?
Tempus AI reported Q2 earnings that technically beat analyst expectations for both revenue and EPS. However, the market is reacting negatively due to a perceived cooling of revenue…
Jul 30, 2026
Corporate Catalyst
Bearish
Impact 75
Why Nancy Pelosi-Owned Tempus AI Stock Is Down After Q2 Earnings
Tempus AI (TEM) reported Q2 revenue of $382.5 million, beating estimates, and a loss of 4 cents per share, also better than expected. The company raised its full-year revenue guida…
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 75
Tempus AI Raises FY2026 Sales Guidance from $1.590B-$1.600B to $1.595B-$1.605B vs $1.593B Est
Tempus AI (TEM) has updated its financial outlook for FY2026, increasing its sales guidance range from $1.590 billion-$1.600 billion to $1.595 billion-$1.605 billion. This upward r…
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 92
Tempus AI Q2 Adj. EPS $(0.04) Beats $(0.14) Estimate, Sales $382.486M Beat $379.743M Estimate
Tempus AI (TEM) announced Q2 adjusted EPS of $(0.04), significantly beating the analyst consensus of $(0.14), and sales of $382.486 million, which also surpassed the $379.743 milli…
Jul 20, 2026
Corporate Catalyst
Bearish
Impact 75
Cathie Wood’s Tempus AI Bet Is Bleeding — And the Chart Looks Worse Than Wall Street Thinks
Tempus AI's announcement of a $1.5 billion all-stock acquisition of Personalis has triggered a significant selloff in TEM shares, primarily due to fears of shareholder dilution. Th…
Jul 20, 2026
Corporate Catalyst
Bearish
Impact 92
Tempus AI Slides as Investors Weigh $1.5 Billion Personalis Acquisition
Tempus AI's acquisition of Personalis for $1.5 billion is a significant strategic move to enhance its position in the rapidly growing minimal residual disease (MRD) market for canc…
Jul 16, 2026
Corporate Catalyst
Bullish
Impact 55
Guggenheim Maintains Buy on Tempus AI, Raises Price Target to $65
Guggenheim analyst Subbu Nambi maintained a 'Buy' rating on Tempus AI (TEM) and raised the price target from $60 to $65. This action signals continued confidence in the company's p…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.